Natco Pharma completes API facility

Natco Pharma Ltd has announced that the Company's API facility situated at Mekaguda village, in Mahaboobnagar District, Andhra Pradesh (which is already approved by the US FDA) has just completed, successfully, an inspection by US FDA for approval of the following additional products :

a) Imatinib Mesylate — medicine for blood cancer;

b) Anastrazole — medicine for breast cancer;

c) Granisetron — treatment for nausea

d) Rizatriptan — for the treatment of migrane.

With these approvals in place, NATCO remains a preferred source of supply for multinational Companies around the world.